Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115

By: via Benzinga
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.